255
Participants
Start Date
October 1, 2021
Primary Completion Date
May 4, 2022
Study Completion Date
May 4, 2022
XC221 100 mg
Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
XC221 200 mg
Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
Placebo
Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
"State budgetary institution of health care of the Yaroslavl region Clinical Hospital No. 2", Yaroslavl
"Limited Liability Company Health Energy", Saint Petersburg
"Limited Liability Company MEDICAL CLINIC", Saint Petersburg
"St. Petersburg State Budgetary Healthcare Institution City Polyclinic No. 117", Saint Petersburg
"Saint Petersburg State Budgetary Healthcare Institution City polyclinic No. 112", Saint Petersburg
"Limited Liability Company Research Center Eco-Security", Saint Petersburg
"St. Petersburg State Budgetary Healthcare Institution City Polyclinic No. 4", Saint Petersburg
"Limited Liability Company Meili", Saint Petersburg
"State autonomous health care institution Engels City Clinical Hospital No. 1", Engel's
Valenta Pharm JSC
INDUSTRY